NYSE$GMED
Globus Medical Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Globus Medical's Q2 2022 results showed revenue growth and strong performance in enabling technologies.
Globus Medical reported a 5.0% increase in worldwide net sales to $263.6 million in Q2 2022. GAAP net income increased by 31.4% to $54.6 million, with diluted EPS at $0.53 and non-GAAP diluted EPS at $0.56. The Enabling Technologies business grew by 41.7% to $29.4 million.
- Worldwide net sales increased by 5.0% to $263.6 million.
- GAAP net income rose by 31.4% to $54.6 million.
- Diluted EPS was $0.53, while non-GAAP diluted EPS was $0.56.
- Enabling Technologies revenue grew by 41.7% to $29.4 million.
Headline financials
Revenue & EPS history
Globus Medical · Revenue · Quarterly
$264M
Revenue by segment
Globus Medical · $264M total across 2 segments · Q2 2022
- Musculoskeletal Solutions$234M+1.7%88.8%
- Enabling Technologies$29.4M+41.7%11.2%
Forward guidance
The Company today reaffirmed its full year 2022 guidance of $1.025 billion in net sales and non-GAAP diluted earnings per share of $2.10.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.8%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.9%
Avg return
30 days after
57%
34 / 60 earnings
Positive
+36.0%
Q3 2025
Best reaction
-23.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -14.6% | -10.4% | |
| Q4 2025 | +4.6% | +2.1% | -8.8% | |
| Q3 2025 | +36.0% | +37.3% | +47.6% | |
| Q1 2025 | -23.0% | -19.7% | -17.3% | |
| Q4 2024 | -4.6% | -4.9% | -12.5% | |
| Q3 2024 | +10.7% | +8.2% | +11.2% | |
| Q2 2024 | +4.0% | +8.0% | +4.4% | |
| Q1 2024 | +22.8% | +28.7% | +31.6% | |
| Q4 2023 | +2.2% | +4.6% | -3.1% | |
| Q3 2023 | -1.4% | -5.1% | -2.5% | |
| Q2 2023 | -5.0% | -4.8% | -9.1% | |
| Q1 2023 | +2.9% | -0.3% | -1.8% | |
| Q4 2022 | -1.2% | -21.9% | -29.2% | |
| Q3 2022 | -4.2% | +9.4% | +11.5% | |
| Q2 2022 | +5.4% | +6.9% | -2.4% | |
| Q1 2022 | +0.1% | +5.2% | +0.1% | |
| Q4 2021 | -3.1% | -3.7% | +1.3% | |
| Q3 2021 | +0.2% | -4.3% | -19.4% | |
| Q2 2021 | -3.3% | -3.0% | +1.3% | |
| Q1 2021 | +3.1% | +3.0% | -0.9% | |
| Q4 2020 | -5.7% | -5.2% | -10.2% | |
| Q3 2020 | +2.4% | +3.5% | +16.9% | |
| Q2 2020 | +18.5% | +13.4% | +13.3% | |
| Q1 2020 | +8.1% | +0.6% | +21.4% | |
| Q4 2019 | -2.1% | -9.7% | -29.0% | |
| Q3 2019 | +3.6% | +4.2% | +8.2% | |
| Q2 2019 | +9.9% | +6.1% | +12.0% | |
| Q1 2019 | -1.9% | -2.0% | -11.0% | |
| Q4 2018 | +0.2% | -2.2% | -0.3% | |
| Q3 2018 | -8.7% | -9.9% | -19.4% | |
| Q2 2018 | +4.7% | +1.7% | +3.5% | |
| Q1 2018 | -3.4% | +0.7% | +12.6% | |
| Q4 2017 | +0.5% | -1.8% | +2.2% | |
| Q3 2017 | +9.8% | +19.7% | +24.3% | |
| Q2 2017 | -5.2% | -3.7% | -1.7% | |
| Q1 2017 | +4.9% | +1.0% | +4.7% | |
| Q4 2016 | -3.1% | -2.1% | +2.5% | |
| Q3 2016 | -5.6% | -4.9% | +7.1% | |
| Q2 2016 | -14.3% | -11.7% | -13.1% | |
| Q1 2016 | -9.4% | — | — | |
| Q4 2015 | +4.2% | — | — | |
| Q3 2015 | +12.3% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2014 | -16.8% | — | — | |
| Q1 2014 | +6.1% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +7.1% | — | — | |
| Q2 2013 | +2.3% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2011 | -20.7% | — | — | |
| Q3 2012 | -16.2% | — | — | |
| Q4 2011 | -0.7% | — | — | |
| Q2 2011 | -0.7% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro